Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery

NCT05428358 | Recruiting

• 1 other identifier: MAGIPAC
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 3

Brief Summary

The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.

Conditions

Liver Metastases; Pancreatic Cancer; Pancreatic Neoplasm

Keywords

magnetic resonance imaging

Outcome Measures

Primary Outcomes (1)

• Change in treatment strategy

  Change in treatment strategy from intended curative resection to other treatment based on MRI scan

  1 week

Secondary Outcomes (8)

• Liver metastases

  1 week

• Surgery

  1 month

• Resection

  1 month

• Intraoperatively detected liver metastases

  1 month

• Overall survival (1-year)

  1 year

Study Arms (1)

Preoperative MRI

EXPERIMENTAL

MRI before surgery.

Diagnostic Test: Preoperative MRI

Interventions

Preoperative MRI DIAGNOSTIC_TEST

Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection

Preoperative MRI

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board
• No liver metastases on CT
• At least 18 years old and able to provide informed consent
• Expected pancreatic ductal adenocarcinoma based on CT scan

You may not qualify if:

• Metastatic disease
• Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment
• Comorbidity rendering major surgery unfeasible (inoperable)
• No informed consent
• Unable to undergo MRI (Kidney insufficiency (eGFR \< 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker)
• Postoperative histology other than adenocarcinoma of pancreato-biliary origin.
• MRI with liver-specific contrast performed during standard workup.

Sponsors & Collaborators

• University of Aarhus: lead
• Rigshospitalet, Denmark: collaborator
• Aalborg University Hospital: collaborator

Study Sites (3)

Aalborg University Hospital

Aalborg, Denmark

RECRUITING

Aarhus University Hospital

Aarhus, 8200, Denmark

RECRUITING

Rigshospitalet

Copenhagen, Denmark

RECRUITING

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Study Officials

• Frank Mortensen, MD, DMSc

  Aarhus University Hospital

  STUDY CHAIR

• Jakob Kirkegård, MD, PhD

  Aarhus University Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jakob Kirkegård, MD, PhD

CONTACT

+4522900604; jakob.kirkegaard@auh.rm.dk

Frank Mortensen, MD, DMSc

CONTACT

+45222517296; frmort@rm.dk

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 16, 2022
• First Posted: June 23, 2022
• Study Start: August 30, 2022
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2028
• Last Updated: April 29, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

DK (3)